Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Akorn, Inc.
WARNING LETTER
•Akorn, Inc.•May 16, 2018

Akorn, Inc. – FDA Warning Letter, May 16, 2018

Record Details

The FDA issued a Warning Letter to Akorn, Inc. following an inspection of their Decatur, IL drug manufacturing facility from April 9 to May 16, 2018. The letter identifies significant violations of current good manufacturing practice (CGMP) regulations, rendering their drug products adulterated.

Key violations include: 1. **Failure to prevent microbiological contamination (21 CFR 211.113(b))**: Observed poor aseptic behavior by operators (e.g., placing heads over open vials, excessive handling of sterile stopper bags, improper wiping), use of non-integral sterile glove and wipe packaging, and inadequate cleanroom design with smoke study deficiencies. The firm's response was deemed insufficient, lacking a comprehensive evaluation of affected batches and commitment to extensive aseptic process redesign. 2. **Inadequate facility design and control systems (21 CFR 211.42(c)(10))**: Deficiencies in environmental and personnel monitoring programs (e.g., lenient glove CFU limits, sanitizing hands before monitoring), and a deficient cleaning program where operators skipped steps and failed to properly sanitize equipment and surfaces. The firm's responses were inadequate, lacking scientific justification for limits and a thorough investigation into the scope of poor cleaning practices. 3. **Failure to follow a written stability testing program (21 CFR 211.166(a))**: Inability to ensure stability for acetylcysteine

Company
Akorn, Inc.
Inspection date
May 16, 2018
Product type
Drugs
Office
Detroit District Office
People
  • Jeffrey D. Meng (Associate Director)
  • Russell K. Riley (Investigator)
View Company Profile

ID · d07fe095-26cd-49a4-a448-3b6512830353

Violation Codes8
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.113(b)21 CFR 211.42(c)(10)21 CFR 211.166(a)FD&C Act 501(a)(2)(B)21 U.S.C. 356C(b)

Full citation text and observation details available on the Dashboard.

Other documents for Akorn, Inc.
  • EIR - 2022-04-08April 8, 2022
  • 483 - 2022-04-08April 8, 2022
  • 483 - 2018-05-16May 16, 2018
  • WARNING_LETTER - 2012-10-02October 2, 2012
  • 483 - 2010-09-17September 17, 2010

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Akorn, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.